OnKure Therapeutics Inc. (OKUR)
OKUR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/0000950170-25-036252-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OKUR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001637715 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$52.7M |
| Operating income | -$54.4M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $110.8M |
| Total assets | $114.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist." | 10-Q 2026-11-04 |
| Cash and burn | $151.4M cash; operating cash flow -$12.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 40,503,094 (2026-11-02); 33,311,787 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-10-07 | Source 2024-10-07 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-08-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Denver, Colorado, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $6K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$17.8M | -$13.1M | $151.4M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$15.3M | -$10.4M | $166.5M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2026 2026-03-31 | Not filed | -$15.2M | -$12.9M | $192.1M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-12-31 | Not filed | -$13.5M | -$11.5M | $59.0M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q3 2025 2025-09-30 | Not filed | -$14.7M | -$13.0M | $70.3M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$15.4M | -$13.3M | $83.4M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2025 2025-03-31 | Not filed | -$15.9M | -$14.0M | $96.7M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2024 2024-12-31 | Not filed | -$17.4M | -$23.4M | $110.8M | No debt tags | $0 | 10-Q 2025-11-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-04 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 405 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.2% |
| 1 month | +12.2% |
| 3 months | -32.6% |
| Year to date | -9.3% |
| 1 year | -16.2% |
| From 52-week high | -50.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CATX | Perspective Therapeutics Inc. | $0.9238 | -2.05% | $111.6M |
| NERV | Minerva Neurosciences Inc | $2.20 | -4.35% | $109.6M |
| PDSB | PDS Biotechnology Corporation | $0.9241 | +5.90% | $113.4M |
| IMUX | Immunic Inc. | $7.23 | -3.86% | $114.8M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| UPB | Upstream Bio Inc. | $2.15 | -22.66% | $117.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier